Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
prolonging spray.
Popular Articles

Covidien Receives FDA Clearance For Its Puritan Bennett 840™ Ventilator System With New Automatic Leak Adjustments Software Option
Covidien (NYSE: COV), a leading global healthcare products company and recognized innovator in mechanical ventilation and respiratory care devices, announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Leak Compensation software feature for the Puritan Bennett 840™ ventilator system. This option provides continuous levels of mechanical ventilation to patients requiring respiratory support, regardless of the level of gas leakage that might occur in the circuit or past a patient interface device in the clinical setting.
generic viagra
The UGR Hill House The First Research Laboratory To Study Risk Conducts When Driving Motorcycles
The University of Granada will house the first European research centre on teenagers" mental mechanisms when driving motorcycles and carrying out risk conducts, which could be helpful, in a near future, to modify and avoid them. The Faculty of Psychology will house three state-of-the-art simulators there was already one at the UGR so far- that will be useful to do research into these mechanisms, thanks to an agreement signed with the company Honda Motor Co. (Europe); the University will become one of the most important centres around the world in this subject.
Zubni implantati
News of the day
New Genetic Study Of Asperger Syndrome, Autistic Traits And Empathy
Scientists from the University of Cambridge have identified 27 genes that are associated with either Asperger Syndrome (AS) and/or autistic traits and/or empathy. The research is published in the journal Autism Research. This is the first candidate gene study of its kind.
Diagnostics

Disease Markers That Will Aid Arthritis Research

A combination of biochemical and MRI markers will allow improved measurement of osteoarthritis (OA) progression. The biomarkers, described in BioMed Central"s open access journal Arthritis Research and Therapy, will be useful for the design and interpretation of trials of new disease modifying drugs. Erik Dam, from Nordic Bioscience, Denmark, worked with a team of researchers to develop and evaluate the markers. He said, "Presently, there is no disease-modifying OA drug with a consistent, documented effect despite several clinical attempts in late stage phases. We believe that effective therapies could be demonstrated, if tools were available that allow identification of rapid progressors for inclusion in trials. With this in mind, we investigated whether combinations of biochemical and MRI-based biomarkers might improve diagnosis and prognosis of knee osteoarthritis". Dam and his colleagues included 159 subjects in their trial. After exclusions, a total of 287 knees were measured. At baseline and after 21 months, biochemical (urinary collagen type II C-telopeptide fragment, CTX-II) and MRI-based markers were quantified. MRI markers included cartilage volume, thickness, area, roughness, homogeneity, and curvature in the medial tibio-femoral compartment. Joint space width, the presently accepted marker for population selection in clinical studies, was measured from radiographs. According to Dam, "The best individual diagnostic marker was cartilage roughness and the best individual prognostic marker was homogeneity. The aggregate cartilage longevity marker (combining CTX-II, volume, area, thickness, congruity, roughness, and homogeneity) performed very well both diagnostically and prognostically - and superior to the individual biochemical and MRI markers. We attribute this to the combination of markers with complementary information about cartilage quantity (e.g. volume), quality (e.g. homogeneity), and breakdown (CTX-II) that together allow superior diagnosis/prognosis". The proposed aggregate marker methodology may have a direct impact on the design of clinical studies. The researchers claim, "By allowing the selection of a high risk population, the study sample size can be lowered while still improving the chance of a positive study outcome. This should facilitate the development of effective drugs". Notes: Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers Erik B Dam, Marco Loog, Claus Christiansen, Inger Byrjalsen, Jenny Folkesson, Mads Nielsen, Arish A Qazi, Paola C Pettersen, Patrick Garnero and Morten A Karsdal Arthritis Research & Therapy (in press) http://arthritis-research.com/ Graeme Baldwin BioMed Central


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009